EURONEXT-PAR$DBVT
DBV Technologies · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported third quarter 2021 financial results and recent regulatory developments.
DBV Technologies reported financial results for the third quarter of 2021. Cash and cash equivalents were $98.2 million as of September 30, 2021. Net loss was $(24.0) million, or $(0.44) per share.
- Cash and cash equivalents totaled $98.2 million as of September 30, 2021.
- The FDA requested a stepwise approach to DBV’s modified Viaskin Peanut (mVP) development program and would like to review the data from DBV’s protein uptake release study prior to providing additional comments on the STAMP protocol design.
- The EMA review of the Viaskin Peanut Marketing Authorization Application is progressing.
- DBV expects that its current cash and cash equivalents will support its operations into the third quarter of 2022.
Headline financials
Revenue & EPS history
DBV Technologies · Revenue · Quarterly
€1.32M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.3%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+11.4%
Avg return
30 days after
47%
20 / 43 earnings
Positive
+21.6%
Q4 2018
Best reaction
-29.8%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.7% | -4.3% | -83.9% | |
| Q3 2025 | -1.2% | -5.4% | -1.4% | |
| Q1 2025 | -4.4% | +4.2% | -7.3% | |
| Q4 2024 | +7.5% | +0.9% | -1.4% | |
| Q3 2024 | -2.5% | -11.3% | +380.9% | |
| Q1 2024 | +3.7% | -14.0% | -15.4% | |
| Q4 2023 | +1.2% | +1.1% | -9.6% | |
| Q3 2023 | -2.9% | -1.9% | -29.5% | |
| Q2 2023 | +1.9% | -2.5% | -3.2% | |
| Q1 2023 | +5.8% | +4.5% | +27.6% | |
| Q4 2022 | -0.7% | +4.1% | +16.6% | |
| Q3 2022 | +2.7% | +2.0% | -9.5% | |
| Q2 2022 | -5.5% | +3.5% | -21.2% | |
| Q1 2022 | -1.6% | +6.2% | +19.4% | |
| Q4 2021 | +3.1% | +0.8% | +22.3% | |
| Q3 2021 | -29.8% | -40.9% | -41.3% | |
| Q2 2021 | -4.4% | -8.1% | +7.7% | |
| Q1 2021 | -1.1% | +0.6% | +21.4% | |
| Q4 2020 | -0.4% | +2.9% | +86.2% | |
| Q3 2020 | +0.0% | -3.5% | -16.4% | |
| Q2 2020 | -3.0% | -3.5% | -16.8% | |
| Q1 2020 | -7.7% | -7.7% | +53.6% | |
| Q4 2019 | -1.2% | +3.6% | -11.7% | |
| Q3 2019 | -0.4% | +4.0% | -13.7% | |
| Q2 2019 | +5.5% | +26.5% | +17.2% | |
| Q1 2019 | -1.7% | +14.3% | +26.5% | |
| Q4 2018 | +21.6% | +34.8% | +16.3% | |
| Q3 2018 | -2.7% | -14.8% | -18.9% | |
| Q2 2018 | -1.9% | -0.1% | -8.2% | |
| Q1 2018 | -1.3% | +3.7% | -4.9% | |
| Q4 2017 | +3.5% | +7.8% | -4.7% | |
| Q3 2017 | +5.5% | -3.4% | +17.2% | |
| Q2 2017 | +1.4% | +1.3% | +25.0% | |
| Q1 2017 | -0.3% | -1.7% | +1.3% | |
| Q4 2016 | -1.1% | -0.4% | -1.0% | |
| Q3 2016 | +1.1% | +1.9% | -2.7% | |
| Q2 2016 | +3.5% | +0.6% | +6.8% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | -2.3% | — | — | |
| Q3 2015 | +3.7% | — | — | |
| Q2 2015 | +4.3% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +5.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro